Tuesday, March 14, 2023
Innocan Pharma Corporation a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property (IP) portfolio, is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for Innocan's patent application number 16/968,627 with claims related to the Company's combined cannabis and magnesium topical pain-relief technology (the "Patent").
The Patent discloses and claims breakthrough magnesium and cannabis-based technology that is administered topically. The technology is designed to systemically relieve pain and/or itching, and is administered via spray, roll-on or lotion.
The Company intends to file further patent applications with the USPTO, as well with other patent offices worldwide, in order to further establish its novel cannabis-based IP portfolio.
Innocan Pharma's CEO, Iris Bincovich, stated, "We are glad to see a robust and vivid indication of our pain relief technology, adding to Innocan's intellectual property portfolio. Receiving the patent approval from the USPTO will assist us in our commercialization efforts."
Source: stockhouse.com
